Lina M. Palacio
A5104632398- Intraperitoneal and Appendiceal Malignancies
- Hormonal Regulation and Hypertension
- Adrenal and Paraganglionic Tumors
- Neuroendocrine Tumor Research Advances
- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Ovarian cancer diagnosis and treatment
Hospital de Sant Joan Despí Moisès Broggi
2024
Pseudomyxoma peritonei (PMP) is a rare and poorly understood malignant condition characterized by the accumulation of intra-abdominal mucin produced from peritoneal metastases. Currently, cytoreductive surgery remains mainstay treatment but disease recurrence death after relapse frequently occur in patients with PMP. New therapeutic strategies are therefore urgently needed for these patients.
<p>BRAF inhibitor suppresses subcutaneous tumor growth in a <i>BRAF</i><sup>V600E</sup> PMP-PDX model. mutant cells from PMP5.1 were subcutaneously implanted mice and treated with vehicle, intraperitoneal cetuximab (20 mg/kg), oral encorafenib or doublet (<i>n</i> = 10–12/group). <b>A,</b> Tumor curve of the overtime. Mean ± SEM is shown. <b>B,</b> Graphs show Western blot quantification pEGFR/EGFR (left) pERK/ERK (right)...
<p>Supplementary Figure 6. Treatment with KRASG12D inhibitor reduces cell viability in mutant PMP-PDXO model a dose dependent manner.</p>
<p>Supplementary Figure 6. Treatment with KRASG12D inhibitor reduces cell viability in mutant PMP-PDXO model a dose dependent manner.</p>
<p>Treatment with BRAF inhibitor is enough to block RAS/ERK signaling pathway and reduce cell viability in PMP models. <i>BRAF</i><sup>WT</sup> (T70) or <i>BRAF</i><sup>V600E</sup> (CTAX34) colorectal cancer PDXO (PMP5.1) PDO (PMP5.2) derived from two different peritoneal metastasis patient 5 treated vehicle, mitomycin C 150 ng/mL, cetuximab 100 μg/mL, encorafenib 1 μmol/L, doublet (encorafenib + cetuximab). <b>A</b>...
<p>Supplementary Figure 4. BRAF inhibitor reduces Phospho-ERK in BRAFV600E mutant PMPPDO and PDXO models a dose dependent manner.</p>
<p>Supplementary Figure 5. Treatment with BRAF inhibitor is enough to prolong RAS/ERK signaling pathway blockage in PMP models.</p>
<p>Supplementary Figure 2. PMP-PDX models resemble histological features of the original patient sample with massive mucinous secretion and preserve invasiveness.</p>
<p>Supplementary Figure 1. PMP preclinical organoid models preserve histological markers and chemotherapy resistance from the original patient sample present different patterns of mucinous secretion.</p>
<p>Supplementary Figure 3. PMP5.1-PDX model preserves oncogenic mutations from the original patient sample.</p>
<p>BRAF inhibitor reduces tumor growth in an orthotopic <i>BRAF</i><sup>V600E</sup> PMP-PDX model. mutant mucinous tissue from PMP5.1 was implanted intraperitoneally mice. Animals were scanned using microCT at day 3 and 6 after implantation. <b>A,</b> Representation of paired volume each mouse Significant differences assessed Unpaired <i>t</i> test (****, <i>P</i> < 0.0001). <b>B–H,</b> Based on the images,...
<div>AbstractPurpose:<p>Pseudomyxoma peritonei (PMP) is a rare and poorly understood malignant condition characterized by the accumulation of intra-abdominal mucin produced from peritoneal metastases. Currently, cytoreductive surgery remains mainstay treatment but disease recurrence death after relapse frequently occur in patients with PMP. New therapeutic strategies are therefore urgently needed for these patients.</p>Experimental Design:<p>A total 120 PMP samples 50...
<p>Supplementary Figure 9. BRAF inhibitors reduce tumor mass in an orthotopic BRAFV600E PMP-PDX model.</p>
<p>Supplementary Figure 9. BRAF inhibitors reduce tumor mass in an orthotopic BRAFV600E PMP-PDX model.</p>
<p>Supplementary Figure 2. PMP-PDX models resemble histological features of the original patient sample with massive mucinous secretion and preserve invasiveness.</p>
<p>Supplementary Figure 7. BRAF signaling pathway inhibition in a subcutaneous BRAFV600E PMP-PDX model.</p>